A Phase 2 Study of Pembrolizumab Immunotherapy for People With Ultra-Rare Sarcomas

Full Title

Purpose

Researchers are finding out if pembrolizumab immunotherapy can be useful to treat some specific types of sarcomas. The people in this study have ultra-rare sarcomas that have come back, gotten worse, or spread after treatment. The diagnoses included in this study are:

• Pleomorphic liposarcoma
• Perivascular epithelioid cell tumor (PEComa)
• Epithelioid sarcoma
• CIC-rearranged sarcoma
• Sclerosing epithelioid fibrosarcoma

Pembrolizumab takes the brakes off the immune system so immune cells can find and hopefully attack cancer cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have one of the ultra-rare sarcoma diagnoses listed above.
• Have recurrence of the sarcoma that got worse or spread further after 1, 2, or 3 types of prior treatment.
• Have recovered from the serious side effects of previous treatments before getting pembrolizumab.
• Have not had prior immunotherapy for your sarcoma.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call Dr. Robert Maki’s office at 646-888-5059.